SCHEMBL6681268

SCHEMBL6681268

COc1cccc(COC(=O)C2=Cc3c(n(C)c(=O)n(Cc4ccccc4)c3=O)N(C)C2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.43
MMP1 P03956 2/20 0.42
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
MMP12 P39900 2/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 2/20 0.40
RXFP1 Q9HBX9 2/20 0.40
PARG Q86W56 2/20 0.40
DPP4 P27487 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680234 0.86 MAPT (0.48) ALDH1A1MAPTKDM4ESMN1; SMN2TP53
SCHEMBL6683557 0.85 MMP1 (0.47) THRBMMP1MMP2MMP9MMP12
SCHEMBL6678517 0.84 THRB (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL7114173 0.84 THRB (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL6684214 0.83 THRB (0.43) THRBMMP1MMP2MMP9MMP12
SCHEMBL6681995 0.80 SMN1; SMN2 (0.48) ALDH1A1KDM4EADORA2BMEN1KMT2A
SCHEMBL6681686 0.77 MMP1 (0.46) THRBMMP1MMP2MMP9MMP12
SCHEMBL6679496 0.75 MMP1 (0.46) THRBMMP1MMP2MMP9MMP12
SCHEMBL7124821 0.75 MMP1 (0.46) THRBMMP1MMP2MMP9MMP12
SCHEMBL6732627 0.74 ALDH1A1 (0.47) THRBMMP1MMP2MMP9MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 THRB 4677/4885MMP1 7/4885MMP2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.